Many recent studies have reported the onset of a robust antibody response to SARS-CoV-2 infection and highlighted produced antibodies' specific qualitative and quantitative aspects, relevant for developing antibody-based diagnostic and therapeutic options. In this review, firstly we will report main information acquired so far regarding the humoral response to COVID-19; we will concentrate, in particular, upon the observed levels and the kinetics, the specificity spectrum and the neutralizing potential of antibodies produced in infected patients. We will then discuss the implication of humoral response's characteristics in the development and correct use of serologic tests, as well as the efficacy and safety of convalescent plasma therapy and of neutralizing monoclonal antibodies for treating infected patients and preventing new infections. An update of the list of newly isolated specific neutralizing antibodies and suggestions for vaccine evaluation and development will be also provided.
Keywords: Convalescent plasma; SARS-CoV-2; humoral response to COVID-19; neutralizing monoclonal antibodies; serologic tests; vaccine design.